(Circulation. 1995;92:183-189.)
© 1995 American Heart Association, Inc.
Articles |
Bradykinin-Induced Vasodilation Is Impaired at the Atherosclerotic Site but Is Preserved at the Spastic Site of Human Coronary Arteries In Vivo
From the Research Institute of Angiocardiology and Cardiovascular Clinic, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Correspondence to Takeshi Kuga, MD, Research Institute of Angiocardiology and Cardiovascular Clinic, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.
Background Bradykinin causes endothelium-dependent vasodilation of isolated human coronary arteries in vitro. However, the effect of bradykinin on vasomotion of human coronary arteries in vivo has not been studied. The aim of this study was to examine whether bradykinin-induced vasodilation is altered at the atherosclerotic or spastic site of human coronary arteries in vivo.
Methods and Results The effect of bradykinin on vasomotion of epicardial coronary arteries was evaluated in 8 patients with normal coronary arteries (control group), 14 patients with organic coronary stenosis (coronary artery disease [CAD] group), and 8 patients with vasospastic angina (VSA group). Changes in the diameter of epicardial coronary artery were assessed by quantitative coronary arteriography. Intracoronary administration of bradykinin at graded doses (60, 200, and 600 ng) dilated epicardial coronary arteries without altering arterial pressure or heart rate in all patients of either group. In the control group, vasomotor responses of the site where acetylcholine caused dilation were compared with the responses of the site where acetylcholine caused constriction. The magnitudes of bradykinin-induced dilation at the site with acetylcholine-induced dilation (mean±SD: 6±6%, 11±9%, and 15±9%) were comparable to that (3±6%, 8±8%, and 13±9%) at the site with acetylcholine-induced constriction. In the CAD group, vasomotor responses of the stenotic site (% diameter stenosis, 15% to 50%) and nonstenotic site were examined. The bradykinin-induced dilation at the stenotic site (0±4%, 3±8%, and 5±9%) was significantly less (P<.01) than at the nonstenotic site (3±4%, 8±6%, and 16±11%) and in the control group. Coronary vasodilation with nitrate at the stenotic site (20±11%) was comparable to that at the nonstenotic site (22±16%) and in the control group (21±10%). In the VSA group, vasomotor responses of the site with acetylcholine-induced spasm and the site without spasm were examined. The bradykinin-induced vasodilation at the spastic site (5±5%, 16±15%, and 33±17%) was comparable to that at the nonspastic site (4±8%, 12±14%, and 21±9%). Nitrate-induced dilation was comparable at the spastic site (51±19%) and the nonspastic site (32±13%). The ratio of bradykinin-induced vasodilation to nitrate-induced vasodilation at the spastic site was comparable to the control group.
Conclusions These results suggest that bradykinin causes vasodilation of human epicardial coronary arteries in vivo and that bradykinin-induced endothelium-dependent vasodilation is impaired at the stenotic site but is preserved at the angiographically normal site where endothelium-dependent vasodilation by acetylcholine is impaired and at the spastic site.
Key Words: bradykinin • vasospasm • atherosclerosis • arteries
This article has been cited by other articles:
 |
|
 |
|
  L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogawa, T. Ohkubo, R. Fukazawa, M. Kamisago, Y. Kuramochi, Y. Uchikoba, E. Ikegami, M. Watanabe, and Y. Katsube Estimation of myocardial hemodynamics before and after intervention in children with kawasaki disease J. Am. Coll. Cardiol., February 18, 2004; 43(4): 653 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mohri, H. Shimokawa, Y. Hirakawa, A. Masumoto, and A. Takeshita Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm J. Am. Coll. Cardiol., January 1, 2003; 41(1): 15 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawano, T. Motoyama, H. Yasue, N. Hirai, H. M. Waly, K. Kugiyama, and H. Ogawa Endothelial function fluctuates with diurnal variation in the frequency of ischemic episodes in patients with variant angina J. Am. Coll. Cardiol., July 17, 2002; 40(2): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Masumoto, M. Mohri, H. Shimokawa, L. Urakami, M. Usui, and A. Takeshita Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina Circulation, April 2, 2002; 105(13): 1545 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sun, M. Mohri, H. Shimokawa, M. Usui, L. Urakami, and A. Takeshita Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina J. Am. Coll. Cardiol., March 6, 2002; 39(5): 847 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Setoguchi, M. Mohri, H. Shimokawa, and A. Takeshita Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease J. Am. Coll. Cardiol., August 1, 2001; 38(2): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, S. Husain, W. Schenke, R. Mincemoyer, N. Epstein, and A. A. Quyyumi Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1467 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E NEWBY Intracoronary infusions and the assessment of coronary blood flow in clinical studies Heart, August 1, 2000; 84(2): 118 - 120. [Full Text] [PDF]
|
|
|
|
|
|
E. Aptecar, E. Teiger, P. Dupouy, C. Benvenuti, M. J. Kern, J. Woscoboinik, S. Sediame, J. M. Pernes, A. Castaigne, D. Loisance, et al. Effects of bradykinin on coronary blood flow and vasomotion in transplant patients J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1607 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taddei, L. Ghiadoni, A. Virdis, S. Buralli, and A. Salvetti Vasodilation to Bradykinin Is Mediated by an Ouabain-Sensitive Pathway as a Compensatory Mechanism for Impaired Nitric Oxide Availability in Essential Hypertensive Patients Circulation, September 28, 1999; 100(13): 1400 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miyata, H. Shimokawa, T. Yamawaki, I. Kunihiro, X. Zhou, T. Higo, E. Tanaka, N. Katsumata, K. Egashira, and A. Takeshita Endothelial Vasodilator Function Is Preserved at the Spastic/Inflammatory Coronary Lesions in Pigs Circulation, September 28, 1999; 100(13): 1432 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Beltrame, S. Sasayama, and A. Maseri Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and caucasian patients J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1442 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Saitoh, T. Saito, T. Ohwada, A. Ohtake, F. Onogi, K. Aikawa, K. Maehara, and Y. Maruyama Morphological and functional changes in coronary vessel evoked by repeated endothelial injury in pigs Cardiovasc Res, June 1, 1998; 38(3): 772 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kato, N. Shiode, T. Yamagata, H. Matsuura, and G. Kajiyama Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis Heart, November 1, 1997; 78(5): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mohri, K. Egashira, T. Tagawa, T. Kuga, H. Tagawa, Y. Harasawa, H. Shimokawa, and A. Takeshita Basal Release of Nitric Oxide Is Decreased in the Coronary Circulation in Patients With Heart Failure Hypertension, July 1, 1997; 30(1): 50 - 56. [Abstract] [Full Text]
|
|